Immunological evaluation of recombinant human serum albuminL7/L12 (Brucella abortus ribosomal protein) fusion protein in animal model
Abstract number: O375
Pakzad I., Rezaee A., Tabaraiee B., Rasaee M., Zavaran Hosseinee A.
Objectives: Brucellosis is the most important common bacterial zoonoses. Various vaccines such as subunit vaccine were proposed for prevention of this disease. The immunogenic Brucella abortus ribosomal protein L7/L12 is a promising candidate antigen for the development of subunit vaccines against brucellosis. In this research, protection of recombinant HSAL7/L12 fusion protein in Balb/c mouse was evaluated.
Methods: The amplified gene was cloned in pYHSA5 vector then pYHSA5L7/L12 construct was transformed in Saccharomyces cerevisiae and expressed protein from supernatant was purified by affinity chromatography column. Balb/c mouses were immunised in four groups by HSAL7/L12 fusion protein (group 1), Brucella abortus S19 (group 2), HSA (group 3), PBS (group 4). ELISA, LTT tests and challenging one week after last injection were carried out. Bacterial count of spleen of immunised Balb/c mouse was done one month after challenging with virulent strain B. abortus 544.
Results: In ELISA test antibody titer HSAL7/L12 fusion protein group was high. In LTT test the differnce of SI in HSAL7/L12 compared with HSA and PBS was significant (p 0.002). Bacterial count of spleen in goup 1 was decreased and the difference of bacterial count of spleen in goup 1 with groups 3 and 4 was significant (P 0.005).
Conclusion: The results indicate that recombinant protein has the ability of proliferating lymphocytes, stimulating humoral immunity and protecting.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|